Adaptive Biotechnologies Corp. (ADPT) Rallies on Earnings Beat, Raised Outlook, and Cash-Flow Targets

Adaptive Biotechnologies (ADPT) reported stronger-than-expected Q3 2026 results, raised its outlook, and reaffirmed profitability expectations. The company's stock has surged 65.73% year-to-date, closing at $26.92 on October 26, 2026. Alger Small Cap Growth Fund highlighted ADPT's diagnostic tools, including clonoSEQ, which was referenced in clinical guidelines for monitoring multiple myeloma.

Original reporting
Published Oct 27, 2026, 2:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 3:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adaptive Biotechnologies Corp. (ADPT) Rallies on Earnings Beat, Raised Outlook, and Cash-Flow Targets — source image
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The article provides a summary of already‑public earnings results, offering little new actionable insight.

02

Market read

Recap of earnings that have been in the market for weeks; limited trading relevance.

03

What to watch

Potential future adoption of clonoSEQ in myeloma guidelines could be material, but not reflected in this recap.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

The piece is an investor‑letter summary highlighting Adaptive Biotechnologies' recent earnings performance and market reaction.

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

The article recaps Adaptive Biotechnologies' Q3 2026 earnings beat, raised outlook and cash‑flow targets, which were already disclosed on July 29, 2026.

Expected impact

limited upside as the market has likely priced the earnings beat already

Evidence & confidence

No fresh data or guidance beyond the July release; traders have already acted on the earnings.

Market effects

Reinforces positive sentiment in the biotech sector but offers no new driver.

Minimal impact on broader US markets.

Limited to investors tracking biotech earnings.

Counterpoint

With the earnings already priced, any further upside is constrained; a pull‑back could occur if expectations rise.

Key entities

  • Adaptive Biotechnologies Corp.

    Biotech firm with FDA‑cleared clonoSEQ test.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.